| 000 | 01893 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516055544.0 | ||
| 264 | 0 | _c20120907 | |
| 008 | 201209s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdr411 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _avan de Schans, S A M | |
| 245 | 0 | 0 |
_aTwo sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cMay 2012 |
||
| 300 |
_a1280-1286 p. _bdigital |
||
| 500 | _aPublication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 | _aCause of Death |
| 650 | 0 | 4 |
_aCyclophosphamide _xadverse effects |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aDoxorubicin _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Large B-Cell, Diffuse _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aNetherlands _xepidemiology |
| 650 | 0 | 4 |
_aPrednisone _xadverse effects |
| 650 | 0 | 4 |
_aRegistries _xstatistics & numerical data |
| 650 | 0 | 4 | _aStandard of Care |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVincristine _xadverse effects |
| 700 | 1 | _aWymenga, A N M | |
| 700 | 1 | _avan Spronsen, D J | |
| 700 | 1 | _aSchouten, H C | |
| 700 | 1 | _aCoebergh, J W W | |
| 700 | 1 | _aJanssen-Heijnen, M L G | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 23 _gno. 5 _gp. 1280-1286 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdr411 _zAvailable from publisher's website |
| 999 |
_c21186307 _d21186307 |
||